USANA HEALTH SCIENCES INC
Financial highlights
| Metric | FY 01/03/26 | FY 12/28/24 | FY 12/30/23 | FY 12/31/22 | FY 01/01/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $925.3M | $854.5M | $921.0M | $998.6M | $1.2B |
| Cost of revenue | $200.9M | $161.2M | $176.7M | $193.9M | $217.9M |
| Gross profit | $724.4M | $693.3M | $744.3M | $804.7M | $968.6M |
| Selling, general & administrative | $337.4M | $263.3M | $257.0M | $262.3M | $279.1M |
| Research and development | $10.7M | $11.6M | $11.4M | $11.6M | $11.1M |
| Operating expenses | $687.0M | $627.0M | $651.2M | $697.1M | $798.4M |
| Operating income | $37.4M | $66.3M | $93.1M | $107.6M | $170.2M |
| Interest expense | $842,000 | $281,000 | $262,000 | $192,000 | $57,000 |
| Pretax income | $41.5M | $76.4M | $102.5M | $108.6M | $170.6M |
| Income tax expense | $30.1M | $34.3M | $38.7M | $39.3M | $54.1M |
| Net income | $10.8M | $42.0M | $63.8M | $69.3M | $116.5M |
| Balance Sheet | |||||
| Cash and equivalents | $158.4M | $181.8M | $330.4M | $288.4M | $239.8M |
| Current assets | $288.4M | $279.2M | $417.7M | $384.4M | $365.1M |
| Total assets | $742.9M | $748.2M | $632.8M | $596.5M | $577.7M |
| Current liabilities | $128.6M | $139.6M | $118.8M | $143.8M | $160.8M |
| Total liabilities | $156.6M | $161.9M | $135.6M | — | — |
| Stockholders' equity | $533.1M | $532.1M | $497.2M | $434.5M | $395.1M |
| Cash Flow Statement | |||||
| Cash from operations | $22.3M | $61.0M | $70.6M | $103.9M | $121.2M |
| Depreciation and amortization | $32.6M | $14.5M | $12.7M | $13.4M | $13.0M |
| Stock-based compensation | $13.8M | $14.6M | $14.6M | $13.3M | $14.3M |
| Capital expenditure | $13.8M | $10.1M | $14.5M | $10.4M | $12.8M |
| Free cash flow | $8.5M | $50.9M | $56.1M | $93.5M | $108.5M |
| Share repurchases | $27.5M | $9.4M | $11.6M | $25.4M | $177.8M |
| Impairments | $6.5M | $0 | $0 | $0 | $0 |
Shares outstanding 18.5M · Free float 50.8%
Annual filing data through FY ended January 3, 2026; float as of July 11, 2026.